BIIB vs IR · P/E 21, rev $9.89B vs P/E 49, rev $3.90B
Biogen Inc (BIIB) versus Ingersoll Rand Inc (IR) — a side-by-side from cached financials, not a winner call.
Biogen Inc (BIIB) is a drug manufacturers - general company listed on NASDAQ.
Ingersoll Rand Inc (IR) is a specialty industrial machinery company listed on US.
Latest reported BIIB revenue for 2025-12-31 was $9.89B. Net income was $1.29B. Revenue was up 2.2% from 2024-12-31 to 2025-12-31. BIIB currently screens at market cap $29.33B and trailing P/E 21.4.
Latest reported IR revenue for 2026-06-30 was $3.90B. Net income was $448.9M. IR currently screens at market cap $28.27B and trailing P/E 48.8.
BIIB currently screens at market cap $29.33B and trailing P/E 21.4. IR currently screens at market cap $28.27B and trailing P/E 48.8.
Not investment advice. Open the BIIB and IR stock pages for the full models.
Not investment advice.